Momentum in Motion

Latest updates, partnerships, and breakthroughs from Aviva Bio

Hormone therapy is undergoing cultural and regulatory re-evaluation, while metabolic medicine and women’s health represent major growth frontiers. d3-T sits at the intersection of these shifts.

Press Releases

Aviva Bio Announces FDA Guidance on Development Pathway for Women’s Testosterone Therapy and New Evidence of a Reduced Risk of Breast Cancer Cell Proliferation for AVA-291

Jan 26, 2026 — In its feedback, the FDA acknowledged the potential breast cancer risk associated with T use in women—a central safety issue that has historically limited the development of a T therapy for women. Read more.

Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025

Jul 14, 2025 — d3-T is a novel, non-aromatizing androgen, offering the benefits of testosterone without converting to estradiol, addressing a known breast cancer risk. Read more.

Aviva Bio Launches to Transform Hormone-Based Medicine— Starting with Women

May 6, 2025 — Aviva Biopharm Inc., a clinical-stage biotech company, launches this month with a mission to rewrite the future of hormone-based medicine. With its lead asset, AVA-291 (d3-Testosterone), Aviva Bio is targeting a long-overlooked need in healthcare: an FDA-approved testosterone therapy for women. Read more.

Events

Upcoming Presentation at AACR Annual Meeting 2026

Aviva Bio will present their poster abstract titled “Effects of AVA-291 (d3-testosterone) versus testosterone on MCF-7 estrogen receptor positive breast cancer cells – lack of aromatization to estradiol leads to a highly differentiated cellular proliferation profile” on April 20, 2026 at AACR 2026 in San Diego.

Presented at ENDO 2025

Aviva Bio presented their poster abstract titled “Characterization of d3-Testosterone, A Novel, Non-Aromatizing Androgen” on July 14, 2025 at Endo 2025 in San Francisco. Review the poster here.